Skip to content

Effect of early mobilisation combined with additional protein on muscle mass in critically ill patients

Effect of early mobilisation combined with additional protein on muscle mass in critically ill patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20948
Enrollment
40
Registered
2018-02-02
Start date
2018-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decline in muscle mass during ICU admission.

Interventions

Intervention group: Optimal feeding (proteins 1.5 g/kg), early mobilization (3 times a day), directly after mobilization additional 15 grams of proteins. Control group: Optimal feeding (proteins 1.5 g

Sponsors

Medisch Spectrum Twente
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Included and randomized in the study within 48 hours after ICU admission. - Expected to stay on the ICU for at least 72 hours. - Complete enteral nutrition. Or enteral nutrition in combination with parenteral or oral nutrition.

Exclusion criteria

Exclusion criteria: -Complete parenteral feeding -> administration of ProSource not possible -Chronic renal failure or hepatic encephalopathy -> absolute contraindications of supplemental protein -Acute kidney injury without CVVH or IHD -> relative contra-indication.22 -Poor prognosis (Anticipated mortality within 72 hours) -Progressive neuro-muscular disease or neurotrauma

Design outcomes

Primary

MeasureTime frame
Muscle thickness of the mid-upper arm, forearm and thigh measured by ultrasonography

Secondary

MeasureTime frame
• muscle quality (echogenicity determined with ultrasonography); • nutritional state and hydration status (Biva measurement); • muscle force (MRC-sum and handgrip force); • functional status (DEMMI); • quality of life (EQ-5D);

Contacts

Public ContactMarieke Kloosterman

Postbus 310

m.kloosterman@rrd.nl+31 (0)53 4875777

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)